Insmed Incorporated (0JAV.L)
USD 72.71
(0.36%)
USD 72.71
(0.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 239.63 Million USD | 25.97% |
| 2022 | 190.23 Million USD | 31.82% |
| 2021 | 144.3 Million USD | 15.87% |
| 2020 | 124.54 Million USD | 10.94% |
| 2019 | 112.25 Million USD | 1414.5% |
| 2018 | 7.41 Million USD | 355.5% |
| 2017 | -2.9 Million USD | -18.99% |
| 2016 | -2.43 Million USD | -23.01% |
| 2015 | -1.98 Million USD | 91.01% |
| 2014 | -22.03 Million USD | -21.45% |
| 2013 | -18.14 Million USD | 15.09% |
| 2012 | -21.36 Million USD | -583.79% |
| 2011 | 4.41 Million USD | -36.18% |
| 2010 | 6.92 Million USD | -33.28% |
| 2009 | 10.37 Million USD | -11.33% |
| 2008 | 11.69 Million USD | 68.26% |
| 2007 | 6.95 Million USD | 1493.39% |
| 2006 | -499 Thousand USD | -480.92% |
| 2005 | 131 Thousand USD | -4.38% |
| 2004 | 137 Thousand USD | -8.67% |
| 2003 | 150 Thousand USD | -92.33% |
| 2002 | 1.95 Million USD | 560.47% |
| 2001 | 296 Thousand USD | 393.33% |
| 2000 | 60 Thousand USD | -92.0% |
| 1999 | 749.73 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 68.11 Million USD | 19.96% |
| 2024 Q1 | 56.78 Million USD | -12.98% |
| 2024 Q3 | 72.25 Million USD | 6.08% |
| 2023 Q2 | 60.63 Million USD | 18.0% |
| 2023 Q4 | 65.25 Million USD | 4.62% |
| 2023 Q3 | 62.36 Million USD | 2.85% |
| 2023 FY | 239.63 Million USD | 25.97% |
| 2023 Q1 | 51.38 Million USD | 11.15% |
| 2022 Q1 | 40.91 Million USD | -4.48% |
| 2022 FY | 190.23 Million USD | 31.82% |
| 2022 Q4 | 46.23 Million USD | -14.8% |
| 2022 Q3 | 54.25 Million USD | 11.13% |
| 2022 Q2 | 48.82 Million USD | 19.33% |
| 2021 FY | 144.3 Million USD | 15.87% |
| 2021 Q3 | 36.57 Million USD | 5.92% |
| 2021 Q4 | 42.83 Million USD | 17.12% |
| 2021 Q2 | 34.52 Million USD | 13.69% |
| 2021 Q1 | 30.37 Million USD | -0.6% |
| 2020 Q3 | 33.02 Million USD | 1.46% |
| 2020 Q1 | 28.42 Million USD | -23.19% |
| 2020 Q4 | 30.55 Million USD | -7.47% |
| 2020 Q2 | 32.54 Million USD | 14.51% |
| 2020 FY | 124.54 Million USD | 10.94% |
| 2019 Q2 | 25.05 Million USD | 41.13% |
| 2019 Q4 | 37 Million USD | 14.03% |
| 2019 FY | 112.25 Million USD | 1414.5% |
| 2019 Q3 | 32.44 Million USD | 29.52% |
| 2019 Q1 | 17.75 Million USD | 139.5% |
| 2018 Q2 | -21.39 Million USD | -23.09% |
| 2018 Q1 | -17.38 Million USD | 19.7% |
| 2018 FY | 7.41 Million USD | 355.5% |
| 2018 Q4 | 7.41 Million USD | 130.7% |
| 2018 Q3 | -24.14 Million USD | -12.86% |
| 2017 FY | -2.9 Million USD | -18.99% |
| 2017 Q1 | -12.58 Million USD | 73.44% |
| 2017 Q4 | -21.64 Million USD | -30.71% |
| 2017 Q2 | -17.23 Million USD | -36.89% |
| 2017 Q3 | -16.56 Million USD | 3.89% |
| 2016 Q4 | -47.39 Million USD | -264.67% |
| 2016 Q3 | -12.99 Million USD | 13.22% |
| 2016 FY | -2.43 Million USD | -23.01% |
| 2016 Q1 | -11.9 Million USD | 9.63% |
| 2016 Q2 | -14.97 Million USD | -25.8% |
| 2015 Q3 | -13.18 Million USD | -6.44% |
| 2015 Q1 | -10.86 Million USD | -504.09% |
| 2015 Q4 | -13.17 Million USD | 0.08% |
| 2015 FY | -1.98 Million USD | 91.01% |
| 2015 Q2 | -12.38 Million USD | -14.03% |
| 2014 Q2 | -9.1 Million USD | 0.0% |
| 2014 Q4 | 2.68 Million USD | 129.29% |
| 2014 FY | -22.03 Million USD | -21.45% |
| 2014 Q1 | - USD | 100.0% |
| 2014 Q3 | -9.17 Million USD | -0.77% |
| 2013 Q1 | - USD | 100.0% |
| 2013 FY | -18.14 Million USD | 15.09% |
| 2013 Q4 | -41.14 Million USD | 0.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q2 | 3.12 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | -100.0% |
| 2012 FY | -21.36 Million USD | -583.79% |
| 2012 Q4 | -8.5 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | 4.41 Million USD | -36.18% |
| 2011 Q2 | 978 Thousand USD | -38.91% |
| 2011 Q1 | 1.6 Million USD | 21.2% |
| 2011 Q3 | 435 Thousand USD | -55.52% |
| 2011 Q4 | 1.4 Million USD | 222.53% |
| 2010 Q1 | 1.92 Million USD | -22.47% |
| 2010 Q4 | 1.32 Million USD | -26.9% |
| 2010 FY | 6.92 Million USD | -33.28% |
| 2010 Q2 | 1.86 Million USD | -3.37% |
| 2010 Q3 | 1.8 Million USD | -3.06% |
| 2009 Q4 | 2.48 Million USD | 0.53% |
| 2009 FY | 10.37 Million USD | -11.33% |
| 2009 Q2 | 3.04 Million USD | 28.27% |
| 2009 Q1 | 2.37 Million USD | -17.1% |
| 2009 Q3 | 2.47 Million USD | -18.59% |
| 2008 Q4 | 2.85 Million USD | -29.77% |
| 2008 Q2 | 2.64 Million USD | 14.29% |
| 2008 Q3 | 4.07 Million USD | 53.74% |
| 2008 Q1 | 2.31 Million USD | -60.52% |
| 2008 FY | 11.69 Million USD | 68.26% |
| 2007 Q4 | 5.86 Million USD | 304.2% |
| 2007 Q3 | 1.45 Million USD | -36.18% |
| 2007 Q2 | 2.27 Million USD | 109.87% |
| 2007 Q1 | 1.08 Million USD | 424.55% |
| 2007 FY | 6.95 Million USD | 1493.39% |
| 2006 Q3 | -405 Thousand USD | -316.58% |
| 2006 Q2 | 187 Thousand USD | 246.3% |
| 2006 Q1 | 54 Thousand USD | 125.0% |
| 2006 Q4 | -334 Thousand USD | 17.53% |
| 2006 FY | -499 Thousand USD | -480.92% |
| 2005 Q1 | 57 Thousand USD | 147.83% |
| 2005 Q2 | 28 Thousand USD | -50.88% |
| 2005 FY | 131 Thousand USD | -4.38% |
| 2005 Q3 | 22 Thousand USD | -21.43% |
| 2005 Q4 | 24 Thousand USD | 9.09% |
| 2004 Q2 | 29 Thousand USD | -52.46% |
| 2004 Q1 | 61 Thousand USD | 125.93% |
| 2004 FY | 137 Thousand USD | -8.67% |
| 2004 Q3 | 24 Thousand USD | -17.24% |
| 2004 Q4 | 23 Thousand USD | -4.17% |
| 2003 Q1 | 62 Thousand USD | 138.46% |
| 2003 FY | 150 Thousand USD | -92.33% |
| 2003 Q4 | 27 Thousand USD | 0.0% |
| 2003 Q3 | 27 Thousand USD | -20.59% |
| 2003 Q2 | 34 Thousand USD | -45.16% |
| 2002 Q1 | 102 Thousand USD | 67.21% |
| 2002 Q2 | 70 Thousand USD | -31.37% |
| 2002 FY | 1.95 Million USD | 560.47% |
| 2002 Q4 | 26 Thousand USD | -98.52% |
| 2002 Q3 | 1.75 Million USD | 2410.0% |
| 2001 FY | 296 Thousand USD | 393.33% |
| 2001 Q4 | 61 Thousand USD | -7.58% |
| 2001 Q3 | 66 Thousand USD | -4.35% |
| 2001 Q2 | 69 Thousand USD | -31.0% |
| 2001 Q1 | 100 Thousand USD | 220.48% |
| 2000 FY | 60 Thousand USD | -92.0% |
| 2000 Q4 | -83 Thousand USD | -122.31% |
| 2000 Q3 | 372 Thousand USD | 295.74% |
| 2000 Q1 | 112 Thousand USD | 0.0% |
| 2000 Q2 | 94 Thousand USD | -16.07% |
| 1999 Q1 | 168 Thousand USD | 0.0% |
| 1999 FY | 749.73 Thousand USD | 0.0% |
| 1999 Q2 | 236 Thousand USD | 40.48% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -10718.736% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -79249.338% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 381.209% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1283.654% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 76660.703% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -1519.812% |
| Imunon, Inc. | -720 Thousand USD | 33382.408% |
| Dynavax Technologies Corporation | 182.11 Million USD | -31.583% |
| Editas Medicine, Inc. | -99.52 Million USD | 340.771% |
| FibroGen, Inc. | 128.9 Million USD | -85.902% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 2605.07% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 79187.459% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 87.029% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 78.075% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 54.246% |
| Verastem, Inc. | -62 Thousand USD | 386608.065% |
| Zoetis Inc. | 5.83 Billion USD | 95.892% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 97.216% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 628.704% |
| Homology Medicines, Inc. | -7.22 Million USD | 3414.912% |
| Nektar Therapeutics | 53.47 Million USD | -348.1% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 82166.781% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1316.483% |
| Perrigo Company plc | 1.68 Billion USD | 85.739% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -227.966% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.097% |
| Illumina, Inc. | 2.74 Billion USD | 91.267% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 98.426% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 95.426% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -2286.327% |
| Waters Corporation | 1.76 Billion USD | 86.394% |
| Biogen Inc. | 7.3 Billion USD | 96.718% |
| Evolus, Inc. | 140.52 Million USD | -70.527% |
| Adicet Bio, Inc. | -6.09 Million USD | 4029.731% |
| bluebird bio, Inc. | -4.03 Million USD | 6046.278% |
| Geron Corporation | -123.5 Million USD | 294.032% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 84.213% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 33.808% |
| Myriad Genetics, Inc. | 476.4 Million USD | 49.699% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 160.09% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 88.952% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 868.858% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 87.417% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 97.88% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 93.084% |
| OPKO Health, Inc. | 318.12 Million USD | 24.673% |
| Exelixis, Inc. | 1.75 Billion USD | 86.366% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 49.645% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 2.004% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 69.219% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 62.374% |
| Blueprint Medicines Corporation | 236.58 Million USD | -1.29% |
| TG Therapeutics, Inc. | 219.1 Million USD | -9.368% |
| Incyte Corporation | 3.44 Billion USD | 93.035% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 30.318% |